AstraZeneca positive primary analysis of Phase 3 trial of its vaccine in the US
- 76% vaccine efficacy against symptomatic COVID-19
- 100% efficacy against severe and critical disease
- 85% efficacy for those aged 65+
That 76% is down from 79% in a statement the firm issued only on Monday.